These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26342249)

  • 1. Advanced qualification of pharmaceutical excipient suppliers by multiple analytics and multivariate analysis combined.
    Hertrampf A; Müller H; Menezes JC; Herdling T
    Int J Pharm; 2015 Nov; 495(1):447-458. PubMed ID: 26342249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PAT-based qualification of pharmaceutical excipients produced by batch or continuous processing.
    Hertrampf A; Müller H; Menezes JC; Herdling T
    J Pharm Biomed Anal; 2015 Oct; 114():208-15. PubMed ID: 26072012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing Excipient Supplier Name and Address Changes in the Pharmaceutical Quality System.
    Rolke R; Ramnarine E; Vinther A; Sawant A
    PDA J Pharm Sci Technol; 2020; 74(2):286-288. PubMed ID: 32179712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
    Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the microbiological quality of pharmaceutical excipients.
    Cundell AM
    PDA J Pharm Sci Technol; 2005; 59(6):381-95. PubMed ID: 16471425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vendor qualification for pharmaceutical excipients--GMP requirements and approach.
    Patel KT; Chotal NP
    Pharmazie; 2010 Nov; 65(11):783-90. PubMed ID: 21155382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
    Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
    J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing Product Confidence-Shifting Paradigms.
    Phillips M; Kashyap V; Cheung MS
    PDA J Pharm Sci Technol; 2015; 69(6):736-42. PubMed ID: 26659104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation into the effects of excipient particle size, blending techniques and processing parameters on the homogeneity and content uniformity of a blend containing low-dose model drug.
    Alyami H; Dahmash E; Bowen J; Mohammed AR
    PLoS One; 2017; 12(6):e0178772. PubMed ID: 28609454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the Variability of Magnesium Stearate and the Correlations With Its Spectroscopic Features.
    Wang T; Potts AR; Hoag SW
    J Pharm Sci; 2019 Apr; 108(4):1569-1580. PubMed ID: 30528196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing of Plasma-Derived Medicinal Products: Qualification Process of Plasma Suppliers.
    Parés C; Martínez M; Messeguer J; Rodríguez E
    PDA J Pharm Sci Technol; 2015; 69(5):620-30. PubMed ID: 26429109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of process analytical technology to crystallization processes.
    Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS
    Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of drug-cyclodextrin formulations using Raman mapping and multivariate curve resolution.
    Vajna B; Farkas I; Farkas A; Pataki H; Nagy Z; Madarász J; Marosi G
    J Pharm Biomed Anal; 2011 Aug; 56(1):38-44. PubMed ID: 21628088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes.
    Kushner J; Langdon BA; Hicks I; Song D; Li F; Kathiria L; Kane A; Ranade G; Agarwal K
    J Pharm Sci; 2014 Feb; 103(2):527-38. PubMed ID: 24375069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the impact of microcrystalline cellulose physicochemical properties on tabletability.
    Thoorens G; Krier F; Rozet E; Carlin B; Evrard B
    Int J Pharm; 2015 Jul; 490(1-2):47-54. PubMed ID: 25981619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-based approach to scheduling audits.
    Rönninger S; Holmes M
    PDA J Pharm Sci Technol; 2009; 63(6):575-88. PubMed ID: 20169864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality and functionality of excipients.
    Pifferi G; Santoro P; Pedrani M
    Farmaco; 1999; 54(1-2):1-14. PubMed ID: 10321025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excipient Taxonomy for the 21st Century.
    Hancock BC; Goldfarb DJ
    J Pharm Sci; 2023 Mar; 112(3):626-633. PubMed ID: 36526004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.